Our Partners

Safe, Secure Blood Supply

The CHS advocates for access to a secure supply of the safest and most efficacious therapies for the treatment of inherited bleeding disorders.

Submission to the Expert Panel on Immune Globulin Product Supply and Related Impacts in Canada

Click here to read the CHS brief.


Submissions on the funding of extended half‐life factor concentrates
Eloctate™ and Alprolix™, extended half-life factor VIII and factor IX for the treatment of hemophilia A and B, are approved by Health Canada. The Canadian Hemophilia Society submitted its recommendations concerning reimbursement in 2014. In 2016, both Canadian Blood Services and Héma-Québec added the two products to the list of those that could be reimbursed through their blood system budgets.

Click here to read the CHS recommendations re Eloctate.

Click here to read the CHS recommendations re Alprolix.